DECA DURABOLIN 50 MG/ML SOLUTION FOR INJECTION (AM

Main information

  • Trade name:
  • DECA DURABOLIN 50 MG/ML SOLUTION FOR INJECTION (AM
  • Dosage:
  • 50 Mg/Ml
  • Pharmaceutical form:
  • Solution for Injection
  • Medicine domain:
  • Humans
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • DECA DURABOLIN 50 MG/ML SOLUTION FOR INJECTION (AM
    Ireland
  • Language:
  • English

Status

  • Source:
  • HPRA - Health Products Regulatory Authority - Ireland
  • Authorization number:
  • PA0261/003/005
  • Authorization date:
  • 12-02-1980
  • Last update:
  • 14-10-2016

Summary of Product characteristics: dosage, interactions, side effects

IRISHMEDICINESBOARDACT1995

MEDICINALPRODUCTS(LICENSINGANDSALE)REGULATIONS,1998

(S.I.No.142of1998)

PA0261/003/005

CaseNo:2036546

TheIrishMedicinesBoardinexerciseofthepowersconferredonitbytheabovementionedRegulationsherebygrantsto

OrganonLaboratoriesLimited

CambridgeSciencePark,MiltonRoad,CambridgeCB40FL,UnitedKingdom

anauthorisation,subjecttotheprovisionsofthesaidRegulations,inrespectoftheproduct

DecaDurabolin50mg/mlSolutionforInjection(ampoule)

TheparticularsofwhicharesetoutinPartIandPartIIoftheattachedSchedule.Theauthorisationisalsosubjecttothegeneralconditionsas

maybespecifiedinthesaidRegulationsaslistedonthereverseofthisdocument.

Thisauthorisation,unlesspreviouslyrevoked,shallcontinueinforcefrom08/06/2007until11/02/2010.

SignedonbehalfoftheIrishMedicinesBoardthis

________________

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/06/2007 CRN 2036546 page number: 1

PartII

SummaryofProductCharacteristics

1NAMEOFTHEMEDICINALPRODUCT

DecaDurabolin50mg/mlSolutionforInjection(ampoule)

2QUALITATIVEANDQUANTITATIVECOMPOSITION

Each1mlcontainsnandrolonedecanoate50mg.

Forexcipients,see6.1.

3PHARMACEUTICALFORM

Solutionforinjection

Aclear,paleyellow,oilysolutionforinjection.

4CLINICALPARTICULARS

4.1TherapeuticIndications

Inthemanagementofconditionsassociatedwithcatabolismandnegativenitrogenbalancesuchasdebility,burns,

osteoporosis,refractoryanaemiaandrenalfailure.

Asanadjunctinthemanagementofdisseminatedmammarycarcinomainthefemale.

4.2Posologyandmethodofadministration

Dosage

Adults:

Theusualinitialdoseis25to50mgonceevery3weeks.Dosesof50mgonceevery3weeksymaybeusedinacute

renalfailure,osteoporosis,ormammarycarcinoma.

Children:

Dosagemaybevarieddependingonthestateofthechildbutshouldnotexceed0.5mg/kgbodyweightonceevery

threeweeks.

Administration

DeepIntramuscularinjection.

4.3Contraindications

Useinpatientswithcarcinomaofprostateortestes,orbreastcarcinomainthemale.

Useduringpregnancy.

Useinpatientsallergictopeanutsorsoya.

Knownhypersensitivitytotheactivesubstanceortoanyoftheaboveexcipients.

4.4Specialwarningsandprecautionsforuse

Ifsignsofvirilisationdevelop,discontinuationofthetreatmentshouldbeconsidered,preferablyinconsultationwith

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/06/2007 CRN 2036546 page number: 2

Thisproductshouldonlybeusedwithgreatcautioninpatientswithrenalfailure,cardiacorliverdysfunction,orin

thosewithahistoryofcoronaryarterydisease,epilepsy,hypertensionormigraine.

Alterationsinglucosetolerancemayoccur,requiringsurveillanceforlatentdiabetes,andpossiblechangesincontrol

fordiabeticpatients.

Patientswithskeletalmetastasesofbreastcarcinomashouldbemonitored.Inthesepatientshypercalcaemiamay

developbothspontaneouslyandasaresultofanabolicsteroidtherapy.Thelattercanbeindicativeofapositivetumor

responsetothehormonaltreatment.Nevertheless,thehypercalcaemiashouldfirstbetreatedappropriatelyandafter

restorationofnormalcalciumlevelshormonetherapycanberesumed.

Fluidretentionmayoccur.

Whenusedinchildrenaccelerationofbonematurationmayoccurwithprematureepiphysealclosure.

Theuseofanabolicsteroidstoenhanceathleticabilitymaycarrysevereriskstotheuser’shealthandshouldbe

discouraged.

SinceDecaDurabolincontainsbenzylalcoholasanexcipient,itshouldnotbeusedinchildrenyoungerthan3years.

4.5Interactionwithothermedicinalproductsandotherformsofinteraction

Concurrentadministrationwithrifampicin,barbiturates,phenytoin,dichloralphenazone,phenylbutazone,

carbamazepinemaydecreaseitseffect.Usewithananticoagulantmayaltertheeffectofthelatter.

Anabolicsteroidsmayimproveglucosetoleranceanddecreasetheneedforinsulinorotherantidiabeticmedicinesin

diabetics.

4.6Pregnancyandlactation

Thedrugmayproducevirilisationofoffspringofwomenreceivingthedrugduringpregnancy.Useistherefore

contraindicated,effectsofuseduringbreastfeedingareuncertainanduseshouldbeavoided.

4.7Effectsonabilitytodriveandusemachines

Noneknown.

4.8Undesirableeffects

Dependentonthedose,frequencyandtotalperiodofadministrationofDeca-Durabolinthefollowingundesirable

effectsmayoccur(seealsoSection4.4):

SystemOrganClass MedDRAterm*

Endocrinedisorders Virilism

Hirsutism

Metabolismandnutritiondisorders Hyperlipidaemia

Psychiatricdisorders Libidoincreased

Vasculardisorders Hypertension

Respiratory,thoracicandmediastinaldisorders Hoarseness

Dysphonia

Gastrointestinaldisorders Nausea

Hepato-biliarydisorders Hepaticfunctionabnormal

Peliosishepatis

Skinandsubcutaneoustissuedisorders Acne

Rash

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/06/2007 CRN 2036546 page number: 3

*MedDRAversion7.1

Thetermsusedtodescribetheundesirableeffectsarealsomeanttoincludesynonymsandrelatedterms.

LivertumorshavebeenreportedoccasionallyonprolongedtreatmentwithorallyactiveC17-alpha-alkylatedanabolic

steroids.ArelationshipbetweenlivertumorsandnonC17-alpha-alkylatedanabolicsteroidssuchasNandroloneesters

appearstobehighlyunlikelybutcannotbeabsolutelyexcluded.

4.9Overdose

Theacutetoxicityofnandrolonedecanoateinanimalsisverylow.TherearenoreportsofacuteoverdosagewithDeca-

Durabolininthehuman.

5PHARMACOLOGICALPROPERTIES

5.1Pharmacodynamicproperties

NandrolonedecanoatehastheATCcode:A14AB01.

Deca-Durabolinisaninjectableanabolicpreparation.ThepharmacologicallyactivesubstanceisNandrolone.The

decanoateestergivesthepreparationdurationofactionofaboutthreeweeksafterinjection.

Nandroloneischemicallyrelatedtothemalehormone.Comparedtotestosterone,ithasanenhancedanabolicand

reducedandrogenicactivity.Thishasbeendemonstratedinanimalbioassaysandexplainedbyreceptorbinding

studies.ThelowandrogenicityofNandroloneisconfirmedinclinicaluse.

Inthehuman,Deca-Durabolinhasbeenshowntopositivelyinfluencecalciummetabolismandtoincreasebonemass

inosteoporosis.Furthermore,Deca-Durabolinhasanitrogen-savingaction.

Thiseffectonproteinmetabolismhasbeenestablishedbymetabolicstudiesandisutilisedtherapeuticallyinconditions

whereaproteindeficiencyexistssuchasduringchronicdebilitatingdiseasesandaftermajorsurgeryandsevere

trauma.Intheseconditions,Deca-Durabolinservesasasupportiveadjuncttospecifictherapiesanddietarymeasuresas

wellasparenteralnutrition.

Androgeniceffects(e.g.virilisation)arerelativelyuncommonattherecommendeddosages.NandrolonelackstheC17-

alpha-alkylgroupthatisassociatedwiththeoccurrenceofliverdysfunctionandcholestasis.

5.2Pharmacokineticproperties

Nandrolonedecanoateisslowlyreleasedfromtheinjectionsiteintothebloodwithahalf-lifeof6days.Theesteris

rapidlyhydrolysedtonandroloneinthebloodwithahalf-lifeofonehourorless.Thehalf-lifeforthecombined

Musculoskeletal,connectivetissueandbone

disorders Epiphysesprematurefusion

Renalandurinarydisorders Urineflowdecreased

Reproductivesystemandbreastdisorders Benignprostatichyperplasia

Priapism

Penisenlarged

Enlargedclitoris

Oligomenorrhoea

Generaldisordersandadministrationsite

conditions Oedema

Injectionsitereaction

Investigations Highdensitylipoproteindecreased

Spermcountdecreased

Haemoglobinincreased

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/06/2007 CRN 2036546 page number: 4

Nandroloneismetabolisedbytheliver.19-norandrosterone,19-noretiocholanoloneand19-norepiandrosteronehave

beenidentifiedasmetabolitesintheurine.Itisnotknownwhetherthesemetabolitesdisplayapharmacologicalaction.

5.3Preclinicalsafetydata

Pharmacologicalstudiesinanimalsonthetoxicityafterrepeateddosing,genotoxicityandcarcinogenicitydidnot

indicateasafetyriskforhumans.Noanimaldataonreproductionareavailable.Theuseofandrogensindifferent

specieshasdemonstratedtoresultinmasculinisationoftheexternalgenitalsoffemalefoetuses.

6PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Benzylalcohol

ArachisOil,refined(peanutoil)

6.2Incompatibilities

Noneknown.

6.3ShelfLife

Unopened:5years.

Theampoulesareintendedforsingleuseonly.

Onceopened,anyunusedsolutionshouldbediscarded.

6.4Specialprecautionsforstorage

Donotstoreabove25 o

Donotrefrigerate.

Keeptheampoulesintheoutercarton.

6.5Natureandcontentsofcontainer

AclearType1glassampoulecontaining1mlofsolution,packedinboxesof3ampoules.

6.6Specialprecautionsfordisposalofausedmedicinalproductorwastematerialsderivedfrom

suchmedicinalproductandotherhandlingoftheproduct

Nospecialrequirements.

7MARKETINGAUTHORISATIONHOLDER

OrganonLaboratoriesLimited

CambridgeSciencePark

MiltonRoad

Cambridge,CB40FL

UnitedKingdom

8MARKETINGAUTHORISATIONNUMBER

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/06/2007 CRN 2036546 page number: 5

9DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

Dateoffirstauthorisation:12February1980

Dateoflastrenewal:12February2005

10DATEOFREVISIONOFTHETEXT

Irish Medicines Board

______________________________________________________________________________________________________________________

Date Printed 12/06/2007 CRN 2036546 page number: 6